Armata Pharmaceuticals, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Armata appointed David House as CFO effective July 17, 2026, with base salary of $371,315/year, 50% annual bonus target (~$185,658), and ~$300,000 annual equity grants. House receives 12 months severance if terminated without cause or for good reason, plus full equity acceleration if involuntary termination occurs within 1 month before or 12 months after a change in control. Separately, Pierre Kyme's employment agreement was amended July 17, 2026 to add identical change-in-control equity acceleration language.
Why this rating
Routine executive hiring/retention at micro-cap biotech. $371K salary + $300K equity = ~$671K annually is material for $21.1M market-cap firm (~3.2% annual cost), but standard CFO comp. Change-of-control provisions are common. No evidence of distress or transformation.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.